Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences ( ($WVE) ) has provided an update. On April 21, 2026, Wave Life Sciences announced that it is advancing plans to redomicile its ...

Wave Life Sciences Plans Redomiciling From Singapore to U.S.

Wave Life Sciences ( ($WVE) ) has shared an announcement. On April 15, 2026, Wave Life Sciences announced plans to restructure its corporate group ...

Wave Life Sciences Plans Redomiciling to Delaware Corporation

Insiders have been trading these 5 stocks: (($BZUN)), (($PONY)), (($ADC)), (($SPRU)) and (($WVE)). Here is a breakdown of their recent trades and t...

Baozun, Pony AI, Agree Realty, Spruce, Wave Shock

In a report released today, Benjamin Burnett from Wells Fargo maintained a Buy rating on Wave Life Sciences, with a price target of $13.00. Accordi...

Wave Life Sciences (WVE) Receives a Buy from Wells Fargo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Wave Life Sciences (WVE) and Kodiak Sciences (KOD) w...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	WVE	$7.31	-0.95%	2.56M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	WVE	$7.31	-0.9%	2.56M
3
4
5
6

WVE

WVE

No Data Available

Get Wave Life Sciences Ltd. Data in Excel

Get Wave Life Sciences Ltd. Data in Excel